SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (269)3/4/1998 3:45:00 PM
From: squetch  Read Replies (1) | Respond to of 717
 
Peter, I only own this one. I have been thinking about DUSA a little bit.

How much of this photosensitivity is going to be reduced in the second or third generations of the competing PDT products. Will they be able to get those next gens to work closer to 732nm?

I did read a study comparing Photofrin and Dusa's compound which made an interesting comment that might relate to PCYC. I have to dig it up.
squetch



To: Biomaven who wrote (269)3/23/1998 8:48:00 PM
From: John O'Neill  Read Replies (1) | Respond to of 717
 
Peter S. Thanks fo info from QLTIF thread. How far ahead is QLT
compared to PCYC. I wonder hoe the poor acceptance (high return rate) of QLTIF CA drugs from the US bodes for the stock?

Maybe the Macular Degeneration is the immediate winner IF it passes safety for repeat TX's.

Any further comments appreciated

JO


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News